# IN VIVO TESTING OF A LEAD COQ10 BIOSYNTHESIS INHIBITOR IN AN SK-BR-3 XENOGRAPH MOUSE MODEL

> **NIH NIH N02** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $42,977

## Abstract

NCATS TDB has been collaborating with Dr Brent Stockwell’s group at Columbia Univ. to develop small molecules inhibitors of CoQ10 biosynthesis for the treatment of cancer. Currently, we have a series of inhibitors that show good potency and selectivity in vitro. We would like to test our lead inhibitor in a mouse model xenografted with SK-BR-3 human breast cancer cells. NCATS does not have in vivo efficacy testing facility nor capacity to run in vivo efficacy models, and therefore must get this service through a contractor.

## Key facts

- **NIH application ID:** 11042051
- **Project number:** 75N95023P00861-P00001-0-1
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** CHRISTOPHER DAMOCI
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $42,977
- **Award type:** —
- **Project period:** 2023-09-26 → 2024-09-25

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11042051

## Citation

> US National Institutes of Health, RePORTER application 11042051, IN VIVO TESTING OF A LEAD COQ10 BIOSYNTHESIS INHIBITOR IN AN SK-BR-3 XENOGRAPH MOUSE MODEL (75N95023P00861-P00001-0-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11042051. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*